“…No abnormalities in urine were detected during therapy. The hemoglobin content in the blood was 13 g per 100 cm 3 , and erythrocytes -4.5 per mm 3 . Leukocyte count was 12,000 per mm 3 -64% of polymorphonuclear cells and 36% of lymphocytes.…”
Section: Analysis Of the Results Of Uncontrolled Clinical Trialsmentioning
confidence: 90%
“…Pain is the most frequent manifestation of the musculoskeletal system diseases, which significantly impairs the quality of life of patients. Diseases of the musculoskeletal system as a cause of disability and mortality are ranked 4th in the world after cardiovascular diseases, cancer diseases and diabetes mellitus (elevated blood sugar level) [1][2][3][4][5]. In Ukraine, approximately 3.5 million people suffer from locomotor system disorders accompanied by musculoskeletal pain [5].…”
Background. The causes of musculoskeletal pain are various diseases of the musculoskeletal system, including osteoporosis, osteochondrosis, arthritis, bone tumors, myalgia, etc. Despite the progress of pharmacology and modern clinical medicine, the problem of pain therapy remains an urgent medical and social problem. One of the preparations of choice for such patients is methocarbomol, a central-acting muscle relaxant whose effect is caused by a general depressant effect on the central nervous system. Objective. The aim of the work is a critical analysis of current scientific data on the safety and efficacy of the use of methocarbamol as a muscle relaxant mediating analgesic action. Methods. Analysis and systematization of current scientific data on clinical study of safety and efficacy of methocarbamol preparations in various pathologies. Results. The results of controlled and uncontrolled clinical trials on the efficacy of methocarbamol have been analyzed, as well as a critical evaluation of data on clinical safety studies. Conclusions. Methocarbamol is characterized by a favorable safety profile when administered either orally or in injectable form. The incidence of side effects does not exceed that of other commonly used myelorelaxants. Methocarbamol has proven to be an effective and safe drug for use as a supplement to exercise regimen (muscle rest), physiotherapy and other activities to ease the discomfort associated with acute musculoskeletal disorders.
“…No abnormalities in urine were detected during therapy. The hemoglobin content in the blood was 13 g per 100 cm 3 , and erythrocytes -4.5 per mm 3 . Leukocyte count was 12,000 per mm 3 -64% of polymorphonuclear cells and 36% of lymphocytes.…”
Section: Analysis Of the Results Of Uncontrolled Clinical Trialsmentioning
confidence: 90%
“…Pain is the most frequent manifestation of the musculoskeletal system diseases, which significantly impairs the quality of life of patients. Diseases of the musculoskeletal system as a cause of disability and mortality are ranked 4th in the world after cardiovascular diseases, cancer diseases and diabetes mellitus (elevated blood sugar level) [1][2][3][4][5]. In Ukraine, approximately 3.5 million people suffer from locomotor system disorders accompanied by musculoskeletal pain [5].…”
Background. The causes of musculoskeletal pain are various diseases of the musculoskeletal system, including osteoporosis, osteochondrosis, arthritis, bone tumors, myalgia, etc. Despite the progress of pharmacology and modern clinical medicine, the problem of pain therapy remains an urgent medical and social problem. One of the preparations of choice for such patients is methocarbomol, a central-acting muscle relaxant whose effect is caused by a general depressant effect on the central nervous system. Objective. The aim of the work is a critical analysis of current scientific data on the safety and efficacy of the use of methocarbamol as a muscle relaxant mediating analgesic action. Methods. Analysis and systematization of current scientific data on clinical study of safety and efficacy of methocarbamol preparations in various pathologies. Results. The results of controlled and uncontrolled clinical trials on the efficacy of methocarbamol have been analyzed, as well as a critical evaluation of data on clinical safety studies. Conclusions. Methocarbamol is characterized by a favorable safety profile when administered either orally or in injectable form. The incidence of side effects does not exceed that of other commonly used myelorelaxants. Methocarbamol has proven to be an effective and safe drug for use as a supplement to exercise regimen (muscle rest), physiotherapy and other activities to ease the discomfort associated with acute musculoskeletal disorders.
“…37 Our findings suggest that smokers may require more frequent pain assessments for optimal pain management because severe pain with hip fracture increases risk of delirium. Paradoxically, delirium risk is increased both with opioid use 38 and with inadequate opioid administration. 39 There are several study limitations.…”
Introduction:Cigarette smoking is a risk factor for hip fractures, while risk factors for developing delirium include older age and preexisting cognitive impairment. We sought to determine whether smoking status is independently associated with delirium and pain outcomes.Methods:This was a prospective, observational cohort study of 442 older adults (65 to 90 years) admitted for traumatic hip fracture at five trauma centers. The primary exposure was smoking status (n = 43, 10%). Additional risk factors included demographics, injury characteristics, and medical interventions. Delirium (primary) and analgesia-related complications were examined with multivariable logistic regression, while analysis of covariance models were used to examine preoperative and postoperative pain scores and opioid consumption (oral morphine equivalents).Results:Smokers had significantly worse outcomes compared with nonsmokers: delirium incidence was 16.3% versus 5.0% (adjusted odds ratio, 4.23; P = 0.005), analgesia complications developed in 30.2% versus 14.8% (adjusted odds ratio, 2.63; P = 0.01), and postoperative opioid consumption was greater (53 mg versus 33 mg, adjusted P = 0.04). Adjusted pain scores were not different between groups.Discussion:Smoking status is associated with markedly worse outcomes in older adults with traumatic hip fracture. Smoking status should be considered in pain management protocols and for early screening and delirium prevention methods.Data availability:On reasonable request.
“…Anesthesia of the posterior hip would require sacral plexus or parasacral sciatic nerve block. The LPB provides superior analgesia over FICB (25), but it is slightly gone out of favor due to the introduction of safe alternative blocks, such as FICB and FNB.…”
: A range of peripheral nerve blocks is available to treat hip fracture pain, leaving clinicians confused on choice. No single block appears to be outstanding. The study described the relevant anatomy, technical approach, risk associated, and practicability to facilitate a better understanding of the various approaches available. The clinician should be able to make an informed decision based on local requirements and logistics.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.